膀胱内纳米颗粒白蛋白结合型紫杉醇治疗既往卡介苗治疗后复发非肌层浸润性膀胱癌的长期生存结局
这项II期试验报告了膀胱内纳米颗粒白蛋白结合型紫杉醇(nab-紫杉醇)治疗既往膀胱内卡介苗(BCG)治疗后复发非肌层浸润性膀胱癌的长期随访结果。28例患者接受500 mg/100 mL nab-紫杉醇、每周1次共6次膀胱灌注,中位随访41个月(范围5-76)。10/28例(36%)达完全缓解,5年总生存率和癌症特异性生存率分别为56%和91%,作者认为nab-紫杉醇是该高危人群的合理治疗选择。
要点
- 28例既往BCG治疗失败的非肌层浸润性膀胱癌患者接受nab-紫杉醇膀胱灌注,中位随访41个月(范围5-76)。
- 10/28例(36%)达完全缓解,6/28例仍无癌,无复发生存率18%,5年总生存率56%、癌症特异性生存率91%。
- 11/28例(39%)行根治性膀胱切除术,其中2/11例(18%)为pT2期或更高分期。
核心结论
- 中位随访41个月时,接受nab-紫杉醇治疗的该队列中18%的患者无病生存。
- 膀胱保留生存率为61%,膀胱癌特异性死亡率为9%。
- 作者认为,nab-紫杉醇是该高危人群的合理治疗选择。
研究设计与样本
- 这是一项II期试验,研究膀胱内nab-紫杉醇用于既往至少1个诱导疗程膀胱内BCG治疗失败后复发的Tis、Ta和T1尿路上皮癌患者。
- 患者接受500 mg/100 mL nab-紫杉醇、每周1次共6次膀胱灌注;完全缓解者接受6个月全剂量维持治疗。
- 共纳入28例患者,中位随访41个月(范围5-76);22例男性、6例女性,中位年龄79岁(范围36-93),既往膀胱内治疗中位数为2。
- 28例患者中21例(75%)为BCG难治性。
- 通过Kaplan-Meier分析评估总生存、无复发生存、膀胱保留生存和癌症特异性生存。
主要发现
- 28例中10例(36%)达完全缓解。
- 28例中6例仍无癌,无复发生存率为18%。
- 5年总生存率和癌症特异性生存率分别为56%和91%。
- 28例中11例(39%)行根治性膀胱切除术,其中11例中2例(18%)为pT2期或更高分期。
临床怎么用
- 作者认为,nab-紫杉醇是该高危人群的合理治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report long-term follow-up results of a phase II trial of salvage intravesical nanoparticle albumin-bound (nab)-paclitaxel for patients with recurrent non-muscle-invasive bladder cancer after previous intravesical bacillus Calmette-Guérin (BCG) therapy. METHODS: This was a phase II trial investigating the use of intravesical nab-paclitaxel in patients with recurrent Tis, Ta, and T1 urothelial carcinoma who failed at least 1 prior induction course of intravesical BCG. Patients received 500 mg/100 mL of nab-paclitaxel in 6 weekly intravesical instillations. Complete responders were offered full-dose maintenance for 6 months. Overall survival, recurrence-free survival, cystectomy-free survival, and cancer-specific survival were assessed via Kaplan-Meier analysis. RESULTS: A total of 28 patients were enrolled with a median follow-up of 41 months (range 5-76). There were 22 men and 6 women with a median age of 79 (range 36-93), and the median number of prior intravesical therapies was 2. Twenty-one of the 28 patients (75%) were BCG refractory. Ten of the 28 patients (36%) achieved complete response. Six of the 28 patients remain cancer free, with a recurrence-free survival rate of 18%. Five-year overall and cancer-specific survival rates were 56% and 91%, respectively. Radical cystectomy occurred in 11 of the 28 patients (39%), of whom 2 out of 11 (18%) had pT2 or greater disease. CONCLUSION: With a median follow-up of 41 months, 18% of this cohort treated with nab-paclitaxel was disease free. Cystectomy-free survival was 61% and bladder cancer-specific mortality was 9%. Nab-paclitaxel is a reasonable treatment option in this high-risk population.
引用
- Robins DJ, Sui W, Matulay JT, et al. Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy. Urology. 2017. PMID: 28163086. doi:10.1016/j.urology.2017.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。